"A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Subjects on Chronic Hemodialysis [GS-US-292-1825]

Administered By

Awarded By

Contributors

Start/End

  • March 15, 2016 - March 14, 2020